Wasatch Advisors LP Sells 447,230 Shares of Exagen Inc. (NASDAQ:XGN)

Wasatch Advisors LP reduced its stake in shares of Exagen Inc. (NASDAQ:XGN - Free Report) by 91.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,975 shares of the company's stock after selling 447,230 shares during the quarter. Wasatch Advisors LP owned 0.24% of Exagen worth $176,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of XGN. Palumbo Wealth Management LLC lifted its holdings in shares of Exagen by 13.5% in the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company's stock worth $355,000 after acquiring an additional 10,340 shares during the last quarter. Geode Capital Management LLC boosted its position in Exagen by 11.9% in the fourth quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock valued at $402,000 after buying an additional 10,442 shares in the last quarter. Corient Private Wealth LLC bought a new stake in shares of Exagen during the fourth quarter worth $45,000. Virtu Financial LLC acquired a new position in shares of Exagen during the fourth quarter worth $46,000. Finally, Kennedy Capital Management LLC lifted its stake in shares of Exagen by 8.8% in the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company's stock valued at $756,000 after acquiring an additional 14,920 shares during the last quarter. Institutional investors and hedge funds own 75.25% of the company's stock.

Exagen Trading Up 11.0 %

XGN traded up $0.53 during trading on Wednesday, reaching $5.37. 114,678 shares of the stock traded hands, compared to its average volume of 87,289. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. The stock's 50-day moving average is $3.86 and its 200 day moving average is $3.80. Exagen Inc. has a 12 month low of $1.32 and a 12 month high of $6.22. The stock has a market capitalization of $96.11 million, a PE ratio of -5.71 and a beta of 1.46.

Wall Street Analyst Weigh In

Several research firms have commented on XGN. Canaccord Genuity Group increased their target price on Exagen from $5.00 to $7.00 and gave the company a "buy" rating in a research report on Friday, January 3rd. Cantor Fitzgerald reiterated an "overweight" rating and set a $8.00 target price on shares of Exagen in a research report on Monday, January 13th. Finally, William Blair reiterated an "outperform" rating on shares of Exagen in a report on Wednesday, March 12th.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).